表紙
市場調査レポート

世界の乳癌市場

Global Breast Cancer Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 306317
出版日 ページ情報 英文 117 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
世界の乳癌市場 Global Breast Cancer Market 2014-2018
出版日: 2014年06月13日 ページ情報: 英文 117 Pages
概要

乳癌は乳房組織における癌細胞の無制御増殖と特徴づけられ、男性、女性の両方が発症します。女性において、乳癌は2番目に多い癌です。乳癌は全癌症例の11.9%を占めています。世界の乳癌市場は2014〜2018年にかけCAGR11.61%で拡大するとみられています。

当レポートでは、世界の乳癌市場の現状と将来的見通しについて調査し、今後の市場規模と成長率、市場動向、市場成長の課題、市場の機会と脅威、主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 当レポートの範囲

  • 市場概要
  • 製品概要
    • 製品プロファイル

第4章 市場調査方法

第5章 イントロダクション

第6章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 乳癌の治療計画

第8章 治療別市場セグメンテーション

第9章 分子別市場セグメンテーション

第10章 乳癌における世界のモノクローナル抗体市場

第11章 臨床パイプラインポートフォリオ

第12章 地域別セグメンテーション

  • 南北アメリカにおける乳癌薬剤市場
    • 市場規模と予測
  • 欧州・中東・アフリカ地域における乳癌薬剤市場
    • 市場規模と予測
  • アジア太平洋地域における乳癌薬剤市
    • 市場規模と予測
    • 国別セグメンテーション

第13章 購買基準

第14章 市場成長牽引因子

第15章 牽引因子とその影響

第16章 市場の課題

第17章 牽引因子と課題の影響

第18章 市場動向

第19章 動向とその影響

第20章 ベンダー環境

  • 競合シナリオ
    • 最新情報
    • 合併・買収
  • 市場シェア分析
    • Hoffmann-La Roche Ltd.
    • Astrazeneca PLC
    • Novartis AG
    • Sanofi-Aventis
    • Eli Lilly and Company
  • その他の注目すべきベンダー
  • 乳癌市場を開拓すると期待される将来の参入企業

第21章 主要ベンダー分析

図表

目次
Product Code: IRTNTR3609

About Breast Cancer

Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer and other undifferentiated carcinoma. Ductal carcinoma is the form of breast cancer which starts in the lining of the milk ducts while lobular carcinoma begins in the milk glands of the breast. When breast cancer spreads from the site of origin to surrounding tissue, it is known as invasive breast cancer. Invasive ductal carcinoma is the most common subtype accounting for 70 to 80 percent of all the breast cases. In women, breast cancer is the second most common form of cancer. GLOBOCAN reported that in the year 2012, breast cancer accounted for 11.9 percent of the total cancer cases and lead to 5,22,000 deaths worldwide.

TechNavio's analysts forecast the Global Breast Cancer market will grow at a CAGR of 11.61 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Breast Cancer market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sale of drugs used for the management of breast cancers including but not limited to:

  • HER2-negative breast cancer
  • HER2-positive breast cancer
  • Hormone receptor positive breast cancer
  • Hormone receptor negative breast cancer
  • Advanced breast cancer
  • Early breast cancer
  • Operable node positive breast cancer
  • Metastatic breast cancer
  • Triple Negative Breast Cancer

The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Breast Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Breast Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC
  • Key Vendors
  • Astrazeneca PLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Sanofi-Aventis

Other Prominent Vendors

  • Accord Healthcare, Inc.
  • Pfizer, Inc.
  • Hospira, Inc.
  • Actavis, Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celldex Therapeutics, Inc.
  • DARA BioSciences, Inc.
  • Eisai Inc.
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hospira, Inc.
  • Immunovative Therapies, Ltd
  • Nektar Therapeutics
  • Nippon Kayaku Co., Ltd
  • Pfizer Inc.
  • Pierre-Fabre Medicament
  • ProStrakan, Inc.
  • Pt Dexa Medica
  • Sorrento Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd

Key Market Driver

  • Increase in Breast Cancer Population.

For a full, detailed list, view our report.

Key Market Challenge

  • Poor Diagnosis and Screening.

For a full, detailed list, view our report.

Key Market Trend

  • Increase in Awareness.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Treatment Regimen for Breast Cancer

08. Market Segmentation by Type of Therapy

09. Market Segmentation by Molecule Type

10. Global Monoclonal Antibodies Market in Breast Cancer

11. Clinical Pipeline Portfolio

12. Geographical Segmentation

  • 12.1. Breast Cancer Drugs Market in the Americas
    • 12.1.1. Market Size and Forecast
  • 12.2. Breast Cancer Drugs Market in the EMEA Region
    • 12.2.1. Market Size and Forecast
  • 12.3. Breast Cancer Drugs Market in the APAC Region
    • 12.3.1. Market Size and Forecast
    • 12.3.2. Country-wise Segmentation of APAC 2013

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2013
    • 20.2.1. F. Hoffmann-La Roche Ltd.
    • 20.2.2. Astrazeneca PLC
    • 20.2.3. Novartis AG
    • 20.2.4. Sanofi-Aventis
    • 20.2.5. Eli Lilly and Company
  • 20.3. Other Prominent Vendors
  • 20.4. Future Players Expected to Tap the Market

21. Key Vendor Analysis

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Breast Cancer Market 2013-2018 (US$ billion)
  • Exhibit 3: List of Breast Cancer Drugs Served by Other Prominent Players
  • Exhibit 4: Staging of Breast Cancer Based on Tumor Size and Extent of Metastasis
  • Exhibit 5: Classification of Breast Cancer Based on Genetic Make-up of Tumor Cells
  • Exhibit 6: Treatment Regimen for Breast Cancer
  • Exhibit 7: Global Breast Cancer Market Segmentation by Type of Therapy 2013 (Revenue in Percentage)
  • Exhibit 8: Molecule Type For Commonly Used APIs in Breast Cancer
  • Exhibit 9: Global Breast Cancer Drugs Market by Geographical Segmentation 2013
  • Exhibit 10: Pain Management Drugs Market in the Americas 2013-2018 (US$ billion)
  • Exhibit 11: Pain Management Drugs Market in the EMEA Region 2013-2018 (US$ billion)
  • Exhibit 12: Breast Cancer Drugs Market in the APAC Region 2013-2018 (US$ billion)
  • Exhibit 11: Country-wise Segmentation of APAC 2013 (revenue in percent)
  • Exhibit 13: 5-Year Survival Rate by Stage of Diagnosis (SEER analysis for 2004-2010)
  • Exhibit 14: Product Portfolio of Roche's Breast Cancer Products in US
  • Exhibit 15: Geography Wise Segmentation for Roche's Products Used in Breast Cancer (in percent)
  • Exhibit 16: Product Portfolio of Astrazeneca's Breast Cancer Products in US
  • Exhibit 17: Geography Wise Segmentation for Astrazeneca Products Used in Breast Cancer (in percent)
  • Exhibit 18: Product Portfolio of Novartis's Breast Cancer Products in US
  • Exhibit 19: Geography Wise Segmentation for Novartis's Breast Cancer Products (in percent)
Back to Top